Clinical Validation of OcuVue™
The OcuVue™ headset provides practical advantages to improve eye care once validated as a reliable tool against the current vision tests. The tests currently on the platform consist of vision field perimetry, acuity, contrast sensitivity, color blindness, Amsler grid screening tests, with many more on the way.
Specialists regularly use these tests during initial vision assessment, diagnosis, and monitoring of progressiveophthalmic conditions such as glaucoma, macular degeneration, ptosis, optic neuritis, scotomas, diabetic retinopathy. It is essential to focus on these prevalent diseases as they frequently go undiagnosed until the treatment interventions and surgical options become limited.
In collaboration with Mount Sinai affiliate practices and New York Eye & Ear Infirmary, our team will be able to test all components of the modular vision screening platform against in-office Gold Standards. We are currently assessing the platform’s virtual reality examinations.
To get more information on our current clinical trials, please visit ClinicalTrials.gov
For more information on the portable vision testing landscape, and how existing technologies have not yet adequately addressed vision testing access disparities, see our team's systematic review in Digital Health.
Software Validation Study
Trial 1: Head-to-head comparison of perimeter-mediated superior visual field measurement using a virtual reality headset and Humphrey Visual Field Analyzer (HVFA) in patients with ptosis (eyelid droop). Pilot phase submitted for publication.
Pilot Trial data accepted by Translational Vision Science & Technology.
Primary endpoints we looked at in this trial are accuracy of perimetry in head-to-head comparison between virtual reality and the HVFA in determining artificial improvement of ptosis after taping and grading its severity.
Secondary end-points included patient’s assessment of speed, comfort and overall preference toward Modular Headset and Gold Standard modalities.
Trial 2: Head-to-head comparison of OcuVue’s™ full virtual reality platform against clinical Gold Standards. Trial data submitted for publication.
Preliminary data from this trial was presented at ARVO ‘22.
What Users Are Saying
“I mean the technology is so simple!”
— Patient on OcuVue™ Technology
“Puts everything [vision tests] togeter, no switching machines is really nice.”
— Clinic Technician on OcuVue™ Technology
“I think the ability to get regular vision screening for early detection would be a big win-win for both doctors and patients.”
— Dr. James Tsai, President New York Eye and Ear Infirmary
“Nothing seems to have changed [for traditional tests] in many years. OcuVue™ was fun!”
— Patient on OcuVue™ Technology
Retinal Camera
Mount Sinai IRB Under Review
This trial will compare Retina Technologies’ retinal camera prototype against an in-office tabletop retinal camera. Under Review.
Machine Learning
Mount Sinai IRB Approved
Access to a large retinal image dataset to train machine learning algorithms to identify eye disease patterns that could be applied towards further remote testing screening. Approved.